

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2020-810 MAY 1 3 2020

TO

ALL HOSPITALS AND HEALTHCARE PROVIDERS

SUBJECT

Reminder on the Risk of QT Prolongation on the Use of

Chloroquine or Hydroxychloroquine

The Food and Drug Administration (FDA) reminds all hospitals and healthcare providers to take extreme caution on the use of Chloroquine or Hydroxychloroquine due to the risk of OT prolongation. The FDA has recorded a total of 30 cases of OT prolongation on the use of the said products from 23 March 2020 to 12 May 2020.1

Chloroquine and hydroxychloroquine should be used with caution in patients with congenital or documented acquired QT prolongation and/or those with known risk factors for QT prolongation such as:

- Cardiac disease e.g. heart failure, myocardial infarction;
- Pro-arrhythmic conditions, e.g. bradycardia (<50 bpm);
- History of ventricular dysrhythmias;

:

:

- Uncorrected hypokalemia and/or hypomagnesemia; and
- During concomitant administration with QT interval prolonging agents e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, antipsychotics, and some antiinfectives (including Azithromycin) as this may lead to an increased risk for ventricular arrhythmias, and sometimes a fatal outcome. 2,3

The magnitude of OT prolongation may increase with increasing concentrations of the drug. Therefore, monitoring of adverse drug reactions should be strictly implemented.

All are enjoined to report adverse drug reactions to FDA through this link: https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH and fill out all the required fields. For inquiries, email us at pharmacovigilance@fda.gov.ph.

ROLANDO ENRIQUE D. DOMINGO, MD
Director General



References:

Cases of QT prolongation on the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Retrieved from https://vigiflow.who-umc.org/searchicsrs

Sanofi-Aventis, S.A. (2020). Hydroxychloroquine sulfate (Plaquenil) [package insert]

Avloclor 250 mg Tablets - Summary of Product Characteristics (SmPC). - (EMC). (2016, October 12). Retrieved April 20, 2020, from https://www.medicines.org.uk/emc/product/5490/smpc

Civic Drive, Filinvest Corporate City, Alabang 1781 Muntinlupa, Philippines Trunk Line +63 2 857 1900 Fax +63 2 807 0751 Website: www.fda.gov.ph Email: info@fda.gov.ph





